Stage IV Ovarian Cancer: Manisha's Survivor Story

Patient Info: Manisha Koirala, Female | Stage IV

She was declared cancer-free after her final chemotherapy cycle on April 30, 2013, and remained in remission more than 6 years later.

Memorial Sloan KetteringRead more →

Breast Cancer: Danièle's Survivor Story

Patient Info: Danièle, Female

Biomarkers: Tumor markers rose from 28 to 58 during early chemotherapy

Danièle completed FEC, cisplatin, 25 radiation sessions, and mastectomy with 18 lymph nodes removed; her surgeon said all cancer had been removed, while recovery included pain, dizziness, arm problems, and emotional distress.

Stage III ROS1 Non-Small Cell Lung Cancer: Wendy's Survivor Story

Patient Info: Wendy, Female | Stage III

Biomarkers: ROS1-positive / ROS1-rearranged

Completed chemoradiation, surgery, and post-surgery radiation for Stage III ROS1-positive NSCLC by January 2017 and later shared a long-term survivor/advocacy story; no explicit NED statement is given.

Lung Cancer Research FoundationRead more →

More than 5 years living with metastatic lung adenocarcinoma after stepwise molecular testing

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 amplification, EGFR L858R mutation, PD-L1 <1%

Metastatic Site: brain, lung

As of April 2026, she remained on gefitinib with no active tumor lesions after complete regression of lung metastases, more than 5 years (66 months) after her original diagnosis.

PubMed CentralRead more →

Severe blood-clotting disorder, liver injury, and reversible kidney injury during treatment for Stage IV lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 about 1%; KRAS mutation

Metastatic Site: bone (right 4th and 5th ribs)

Restaging before cycle 4 showed a partial response. Cancer treatment was then interrupted as severe acquired iTTP, cholestatic liver injury, and reversible acute kidney injury required intensive management.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage IIA triple-negative neuroendocrine breast carcinoma with chemoimmunotherapy response

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Triple-negative neuroendocrine breast carcinoma with PD-L1 CPS >=10, and reported germline BRCA1/2 mutation.

As of March 2025, 12 months after surgery, follow-up imaging and tumor-marker testing showed no local recurrence or distant metastasis, and she remained in good general condition.

PubMed CentralRead more →

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed CentralRead more →

Stage IV PD-L1-high lung adenocarcinoma: remission on chemotherapy after tislelizumab-associated KLHL11-IgG cerebellitis

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-high lung adenocarcinoma with EGFR/ALK/ROS1 wild type and TTF-1 positive. KLHL11-IgG was linked to cerebellitis.

Metastatic Site: M1a disease; specific metastatic site not otherwise…

At 1-year neurologic follow-up, the cerebellitis had markedly improved, serum KLHL11-IgG was negative, brain MRI lesions had resolved, and lung adenocarcinoma remained in remission on cisplatin plus pemetrexed.

PubMed CentralRead more →

Small Cell Lung Cancer: Montessa's Survivor Story

Patient Info: Montessa, Female, Under 40

As of June 2026, Montessa was sharing her recovery after limited-stage small cell lung cancer treatment with concurrent chemotherapy and radiation followed by brain radiation.

The Patient StoryRead more →

Stage III Non-Small Cell Lung Cancer: Heidi's Survivor Story

Patient Info: Heidi N., Female, 50s | Stage III

Biomarkers: No targetable mutation identified

As of June 2026, Heidi was featured as a lung cancer advocate after treatment for inoperable Stage IIIA NSCLC; scans through January 2021 had shown no evidence of disease.

The Patient StoryRead more →

Stage II KRAS Lung Adenocarcinoma: Roy's Survivor Story

Patient Info: Roy, Male, 50s | Stage II

Biomarkers: KRAS

As of May 2026, Roy described being cancer-free/in remission, back to flying professionally, and strong enough to complete his 5th marathon at the Boston Marathon.

The Patient StoryRead more →

Lung cancer treated with tislelizumab: rare fluid buildup around the lung as a side effect

Patient Info: Anonymized, Male, 60s

After treatment of the bronchial-stump recurrence, the tumor remained stable. The delayed pleural effusion resolved within 10 days of methylprednisolone, and tumor stability continued for the next 15 months.

PubMed CentralRead more →

More than 5 years of disease control with maintenance chemotherapy for Stage IV lung cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: KRAS mutation; TP53 mutation

Metastatic Site: brain

After more than 60 months of follow-up and prolonged maintenance chemotherapy, the latest assessment found no evidence of current tumor progression.

PubMed CentralRead more →

Stage IV squamous NSCLC: durable pembrolizumab response followed by invasive aspergillosis, marrow failure, and death

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 20%

Metastatic Site: bilateral lungs

After durable partial response to pembrolizumab-based therapy, he developed severe pulmonary infection, invasive pulmonary aspergillosis, progressive AA-like bone marrow failure with severe cytopenias, declined further treatment, and died at home in early 2025.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Phil's Survivor Story

Patient Info: Phil Bosanko, Male, 40s | Stage IV

Metastatic Site: Liver

As of February 2026, Phil was alive and cancer-free nearly 20 years after a Stage IV colon cancer diagnosis with extensive liver metastases.

City of HopeRead more →

Large-Cell Neuroendocrine Cancer of the Cecum in Familial Adenomatous Polyposis

Patient Info: Anonymized, female

Biomarkers: Pathogenic germline APC mutation; KRAS ; PALB2 mutation; microsatellite stable with intact mismatch-repair proteins

At 18 months after the initial right colectomy, there was no pathologic, clinical, or imaging evidence of recurrence.

PubMed CentralRead more →

Localized male small-cell neuroendocrine breast cancer with complete response

Patient Info: Anonymized, Male, 40s

Biomarkers: Synaptophysin-positive; weak cytokeratin-positive; HER2-negative; Ki-67 greater than 70%; genetic testing not performed

The tumor shrank substantially during neoadjuvant cisplatin/etoposide. Modified radical mastectomy then showed a complete pathologic response and 17 reactive axillary lymph nodes; the patient remained disease-free after 18 months of follow-up.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed CentralRead more →

Stage 4 lung cancer: persistent cough led to diagnosis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS and TP53 ; PD-L1 TPS 95%. Other common lung drivers were not detected.

Metastatic Site: liver, left adrenal gland, lymph nodes, pleural…

After more than 2 years of disease control and partial response on antiangiogenic therapy plus sintilimab, the patient developed fulminant immune-checkpoint-inhibitor-induced type 1 diabetes with severe diabetic ketoacidosis, inflammatory crisis, sepsis, and died shortly after discharge against medical advice.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma with suspected myocardial metastasis responding to afatinib plus chemotherapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR L861Q; PD-L1 TPS/CPS 65%. TP53, MET and PIK3CA alterations also reported.

Metastatic Site: left ventricular myocardium; mediastinal lymph nodes…

As of December 2025, the suspected left-ventricular myocardial metastasis had shrunk after 2 courses of afatinib plus pemetrexed/cisplatin, and the patient had no cardiovascular events during monitoring.

PubMed CentralRead more →

Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion: stable disease on ivonescimab plus pemetrexed

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion persisted. Later pleural fluid had PD-L1 TPS 40% / CPS 41, low TMB

Metastatic Site: pleura / malignant pleural effusion

As of August 2025, Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion was stable on ivonescimab plus pemetrexed after prior progression on gefitinib, almonertinib, and ivonescimab monotherapy.

PubMed CentralRead more →

Primary pulmonary osteosarcoma resected after discovery as a small lung nodule

Patient Info: Anonymized, Male, 60s

Biomarkers: Primary pulmonary osteosarcoma markers: SATB2 positive, Ki-67 ~30%, p53 mutant-pattern staining; epithelial markers negative.

After complete wedge resection with negative margins and 6 cycles of adjuvant liposomal doxorubicin/cisplatin, no recurrence or metastasis was observed during 9 months of follow-up.

PubMed CentralRead more →

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed CentralRead more →